Ultromics, a spun-out from the Oxford University, is a maker of an AI-supported cardiac-decision-support tool that is championing a new era of medical diagnosis through innovating automated tools to support physicians in the detection of cardiovascular disease.
Ultromics provides autonomous echocardiography analysis, empowering physicians to make fast, accurate diagnostic decisions.
Ultromics was founded in 2017 by Ross Upton and Professor Paul Leeson. The company is headquartered in Oxford, Oxfordshire, United Kingdom.
Ultromics is setting new standards for world-class cardiovascular diagnostic tools, together with clinicians and powered by artificial intelligence.
Ultromics' technology uses AI in order to help scan through echocardiograms and look for heart disease or other issues. It was designed to be “plugged in” to a system in the U.S. and in Europe. The system can measure left ventricle ejection fraction and global longitudinal strain volume.
Ultromics' The EchoGo suite provides automated solutions to support physicians in detecting cardiovascular disease. Echocardiogram images are automatically sent to Ultromics for analysis and artificial intelligence assists in identifying suspected heart disease, sending a report back within minutes. The system is zero click and has zero variability.
Ultromics is backed by Oxford Sciences Innovation, Mayo Clinic, Neptune, RT Ventures, GT Healthcare, Tanarra, Fushia, Woodford Investment Management and others. The company raised $10M in Series B round on June 15, 2020. This brings Ultromics' total funding to $25M to date.